PTC/SB/08a (08-03)
Approved for use through 97/31/2006, ONE 0651-0231
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

	Application Number			
	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor KAISI		ER	
( Not for submission under 37 CFR 1.99)	Art Unit			
,	Examiner Name			
	Attorney Docket Number	r	39893/44978	

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>				Pages,Columns,Lines where Relevant Passages or Relevar Figures Appear				
	1										
If you wis	h to a	l dd additional U.S. Pater	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Patentee or Applicant of cited Document Pages, Co. Relevant Figures A		Columns,Lines where nt Passages or Relevant Appear			
	1										
If you wis	h to a	dd additional U.S. Publi		p		, , , , , , , , , , , , , , , , , , , ,		d button	$\overline{}$		
				FOREIG	SN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	vhere Rel	or Relevant	74
	1	945 582	EP		A3	2003-08-27	Oliver et al.				
	2	1 323 885	EP		A2	2003-07-02	Schwarz				
	3	32 50 129	DE		C2	1982-06-25	Mayer et al.				

# Application Number Fing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 199) Application Number Fing Date First Numed Inventor | KAISER | Art Unit | Examiner Name | Attorney Docket Number | 39893/44978

Α1

DE

1999-08-12 Artmeier et al

Date Considered

	5	878 600	EP	A3	2000-01-05	Steiert			
	6	101 25 518	DE	A1	2001-05-23	Woppel et al.			
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	Add		
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials* Cite (Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5	
	1								

1 See Kind Cooker of USPTO Patient Documents at year <u>USPTO\_ROD</u> or WIFEP 901.64. <sup>2</sup> Eatine office that instead the document, by the how-litter code (WIFD Standard ST3.) <sup>3</sup> For Junpance patient concurrent, by a conclusion to be year of the Empore transper patient person the series and number of the patient document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIFO Standard ST.16 if possible. <sup>3</sup> Applicant is to place a check mark here if English Imaguage Internations in attacket.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

4 199 38 253

Examiner Signature

# Application Number Filing Date Filing Date

### CERTIFICATION STATEMENT

10000 000 01 01 11 1101	and most to maile are appropriate sensetarite).	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. Sec 37 CFR 197(eV1)

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. Sea 7 CFR 1976(c)

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Diagon one 37 CER 1 07 and 1 98 to make the appropriate colortion(c)

□ None

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/perry palan/	Date (YYYY-MM-DD)	2006-06-29
Name/Print	Perry Palan	Registration Number	26213

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, V.S. Organized to Complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, V.S. Organized to Comment of Commen

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolffice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet of sicklosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via filed in application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.